Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)R. Charles Coombes, Stuart McIntosh, Matthew Krebs et al.|Cancer Research|2022Cited by 7